Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies
- 8 November 2025
- journal article
- review article
- Published by Elsevier in Transplantation and Cellular Therapy
Abstract
No abstract availableKeywords
Funding Information
- Leukemia and Lymphoma Society
This publication has 54 references indexed in Scilit:
- Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s LymphomaClinical Pharmacokinetics, 2024
- Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeTransplantation and Cellular Therapy, 2023
- Cellular kinetics: A clinical and computational review of CAR-T cell pharmacologyAdvanced Drug Delivery Reviews, 2022
- Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19JAMA, 2022
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T ImmunotherapiesCell, 2020
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaMolecular Therapy, 2017
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016